Get Premium to unlock powerful stock data
Sierra Oncology Inc logo

Sierra Oncology Inc

$ 54.75 +0.02 (+0.04%) 10:08 PM EST
P/E:
At Loss
P/B:
4.97
Market Cap:
$ 1.34B
Enterprise V:
$ 1.07B
Volume:
197.43K
Avg Vol (2M):
746.38K
Also Trade In:
Volume:
197.43K
Market Cap $:
1.34B
PE Ratio:
At Loss
Avg Vol (2-Month):
746.38K
Enterprise Value $:
1.07B
PB Ratio:
4.97
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Sierra Oncology Inc
NAICS : 325412 SIC : 2834
1820 Gateway Drive, Suite 110, San Mateo, USA, 94404
Description
Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.
Name Current Vs Industry Vs History
Cash-To-Debt 48.79
Equity-to-Asset 0.93
Debt-to-Equity 0.02
Debt-to-EBITDA -0.06
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -3.77
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 84.14
9-Day RSI 84.7
14-Day RSI 82.46
6-1 Month Momentum % 145.21
12-1 Month Momentum % 207.38

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 21.27
Quick Ratio 21.27
Cash Ratio 20.95

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -103.1
Name Current Vs Industry Vs History
ROE % -80.4
ROA % -73.49
ROIC % -1767.31
ROC (Joel Greenblatt) % -12638.51
ROCE % -79.5

Financials (Next Earnings Date:2022-08-05 Est.)

SRRA's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:SRRA

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -6.77
Beta 0.3
Volatility % 33.67
14-Day RSI 82.46
14-Day ATR ($) 0.544772
20-Day SMA ($) 54.571
12-1 Month Momentum % 207.38
52-Week Range ($) 14.91 - 54.97
Shares Outstanding (Mil) 24.42

Piotroski F-Score Details

Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Sierra Oncology Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More